Starting Strength is the bestselling book on the most fundamental and effective approach to strength training ever written. Mark Rippetoe hosts Starting Strength Radio where he discusses topics of interest, primarily to him, but perhaps also to you.
…
continue reading
Audioboom and Not So Different: a Podcast from The Center for Biosimilars에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Audioboom and Not So Different: a Podcast from The Center for Biosimilars 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!
Player FM 앱으로 오프라인으로 전환하세요!
S6 Ep4: Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
Manage episode 357041818 series 2161808
Audioboom and Not So Different: a Podcast from The Center for Biosimilars에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Audioboom and Not So Different: a Podcast from The Center for Biosimilars 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Show notes
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars
IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years
https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years
Vizient Report Predicts Over 3% Inflation Rate for Biologics
https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars
Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations
https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations
Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars
https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars
IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years
https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years
Vizient Report Predicts Over 3% Inflation Rate for Biologics
https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars
Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations
https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations
Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars
https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars
157 에피소드
Manage episode 357041818 series 2161808
Audioboom and Not So Different: a Podcast from The Center for Biosimilars에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Audioboom and Not So Different: a Podcast from The Center for Biosimilars 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Show notes
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars
IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years
https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years
Vizient Report Predicts Over 3% Inflation Rate for Biologics
https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars
Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations
https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations
Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars
https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars
IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years
https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years
Vizient Report Predicts Over 3% Inflation Rate for Biologics
https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars
Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations
https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations
Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars
https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars
157 에피소드
All episodes
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.